Breckenridge Pharmaceutical, Inc.
NDC labeler code: 51991
What is a labeler?
The company whose name is on the package and in the FDA’s National Drug Code (NDC) Directory. It may make the medicine itself or sell medicine made by another company. The first part of every NDC code identifies the labeler.
Official FDA data only
Products, approvals and recalls come from the FDA (NDC Directory, Drugs@FDA, enforcement reports). Recalls are linked to this company by the NDC labeler code on the recalled product.
Questions about your medicine: ask your doctor or pharmacist. In an emergency, call 911.
Prescription medicines
- EverolimusYulithira, Zortress, Torpenz · 11 products
- OxcarbazepineTrileptal, Oxtellar XR · 6 products
- AsenapineSaphris, Secuado · 5 products
- Milnacipran hydrochlorideSavella · 4 products
- LacosamideVimpat, Motpoly XR · 4 products
- DuloxetineDrizalma Sprinkle · 4 products
- Propranolol hydrochlorideInderal La, Innopran XL, Inderal XL · 4 products
- PomalidomidePomalyst · 4 products
- Trimipramine maleate3 products
- RivastigmineRivastigmine Transdermal System, Exelon · 3 products
- DesvenlafaxinePristiq Extended-Release · 3 products
- TofacitinibXeljanz, Xeljanz XR · 2 products
- Tetracycline hydrochloride2 products
- Zolpidem tartrateAmbien CR, Edluar, Ambien · 2 products
- Estradiol and norethindrone acetateLopreeza, Etyqa, Combipatch (Estradiol/Norethindrone Acetate Transdermal System) · 2 products
- Methscopolamine bromide2 products
- EplerenoneInspra · 2 products
- PenicillamineCuprimine, Depen, Aagylur · 1 product
- Methylergonovine maleateMethergine · 1 product
- Norepinephrine bitartrateLevophed · 1 product
- Butalbital, acetaminophen, caffeine and codeine phosphate1 product
- AnastrozoleArimidex · 1 product
- LetrozoleFemara · 1 product
- AlcoholDehydrated Alcohol · 1 product
- Terbinafine hydrochloride1 product
- Methadone hydrochlorideMethadone Hydrocloride Dye-Free, Sugar-Free, Unflavored, Methadose Dispersible, Methadose Sugar-Free · 1 product
- Butalbital, aspirin, caffeine and codeine phosphateAscomp with Codeine · 1 product
- GranisetronGranisol, Sustol, Sancuso · 1 product
- ExemestaneAromasin · 1 product
FDA applications for these products
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Approved | Application | Medicine | Sponsor |
|---|---|---|---|
| June 3, 2026 | ANDA209633 | Tofacitinib TOFACITINIB CITRATE | Breckenridge |
| June 23, 2025 | ANDA219444 | Alcohol DEHYDRATED ALCOHOL | Breckenridge |
| January 28, 2025 | ANDA217640 | Everolimus EVEROLIMUS | Natco |
| December 16, 2024 | ANDA218252 | Methadone hydrochloride METHADONE HYDROCHLORIDE | Breckenridge |
| March 17, 2022 | ANDA204921 | Lacosamide LACOSAMIDE | Msn Labs Pvt Ltd |
| August 23, 2021 | ANDA215409 | Penicillamine PENICILLAMINE | Breckenridge |
| May 20, 2021 | ANDA205432 | Everolimus EVEROLIMUS | Breckenridge |
| March 5, 2021 | ANDA205426 | Everolimus EVEROLIMUS | Breckenridge |
| January 22, 2021 | ANDA214455 | Norepinephrine bitartrate NOREPINEPHRINE BITARTRATE | Breckenridge |
| December 10, 2020 | ANDA205960 | Asenapine ASENAPINE MALEATE | Breckenridge |
| October 30, 2020 | ANDA210111 | Pomalidomide POMALIDOMIDE | Breckenridge |
| June 4, 2020 | ANDA213592 | Zolpidem tartrate ZOLPIDEM TARTRATE | Breckenridge |
| November 26, 2019 | ANDA209063 | Rivastigmine RIVASTIGMINE | Breckenridge |
| February 21, 2019 | ANDA211031 | Exemestane EXEMESTANE | Breckenridge |
| November 7, 2018 | ANDA210662 | Tetracycline hydrochloride TETRACYCLINE HYDROCHLORIDE | Breckenridge |
| September 14, 2018 | ANDA208283 | Eplerenone EPLERENONE | Breckenridge |
| April 15, 2016 | ANDA208127 | Trimipramine maleate TRIMIPRAMINE MALEATE | Breckenridge |
| January 27, 2016 | ANDA205071 | Milnacipran hydrochloride MILNACIPRAN HYDROCHLORIDE | Breckenridge |
| June 29, 2015 | ANDA204003 | Desvenlafaxine DESVENLAFAXINE SUCCINATE | Alembic |
| June 11, 2014 | ANDA203088 | Duloxetine DULOXETINE HYDROCHLORIDE | Breckenridge |
| December 6, 2011 | ANDA040642 | Methscopolamine bromide METHSCOPOLAMINE BROMIDE | Breckenridge Pharm |
| July 15, 2011 | ANDA078703 | Propranolol hydrochloride PROPRANOLOL HYDROCHLORIDE | Adare Pharms Inc |
| June 3, 2011 | ANDA200161 | Letrozole LETROZOLE | Natco Pharma Ltd |
| September 13, 2010 | ANDA040889 | Methylergonovine maleate METHYLERGONOVINE MALEATE | Breckenridge |
| June 28, 2010 | ANDA079220 | Anastrozole ANASTROZOLE | Natco Pharma Ltd |
Show the other 6 applications
| Approved | Application | Medicine | Sponsor |
|---|---|---|---|
| June 4, 2010 | ANDA077714 | Terbinafine hydrochloride TERBINAFINE HYDROCHLORIDE | Breckenridge Pharm |
| June 22, 2009 | ANDA078969 | Granisetron GRANISETRON HYDROCHLORIDE | Natco Pharma |
| April 17, 2008 | ANDA078324 | Estradiol and norethindrone acetate ESTRADIOL AND NORETHINDRONE ACETATE | Breckenridge Pharm |
| January 11, 2008 | ANDA078069 | Oxcarbazepine OXCARBAZEPINE | Breckenridge Pharm |
| June 10, 2004 | ANDA076560 | Butalbital, acetaminophen, caffeine and codeine phosphate BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE | Lgm Pharma |
| November 30, 2001 | ANDA075231 | Butalbital, aspirin, caffeine and codeine phosphate BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE | Lgm Pharma |
The sponsor is the company that holds the FDA application; it can differ from the labeler.
Recall timeline
2026
-
June 4, 2026 · Class II · Ongoing · D-0583-2026 · Duloxetine
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Duloxetine Delayed-Release Capsules, USP, 60mg, packaged in a) 90 Capsules (NDC 51991-748-90); b) 1000 Capsules (51991-748-10), Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by
-
June 4, 2026 · Class II · Ongoing · D-0582-2026 · Duloxetine
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Duloxetine Delayed-Release Capsules, USP, 30mg, 1000 Capsule bottles, Rx only, Manufactured. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Distributed by: Breckenridge Pharmaceuticals, Inc., Berke
-
April 21, 2026 · Class II · Ongoing · D-0522-2026 · Duloxetine
CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
Duloxetine Delayed-Release Capsules USP, 60mg, Rx Only, 90-count bottle, Mfr. by Towa Pharmaceutical Eurpoe S.L., Martorelles, (Barcelona), Spain, Dist. by. Breckenridge Pharmaceutical, Inc., Berkely Heights, NJ 07922, N
2025
-
November 24, 2025 · Class II · Ongoing · D-0216-2026 · Duloxetine
CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
Duloxetine Delayed-Release Capsules, USP, 60 mg, 1000-Capsule bottles, Rx Only, Manufactured by: Towa Pharmaceuticals Europe, S.L. Marotrelles, (Barcelona), Spain, Distributed by: Breckenridge Pharmaceutical Inc., Berkel
-
October 9, 2025 · Class II · Ongoing · D-0100-2026 · Duloxetine
CGMP Deviations: N-nitroso-duloxetine impurity above the safety assessment limit of 12.5ppm.
Duloxetine Delayed-Release Capsules, USP, 60 mg, a.) 90-count bottle (NDC: 51991-748-90), b.)1000-count bottle (NDC 51991-748-10),Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain; Dist.
-
July 15, 2025 · Class II · Ongoing · D-0552-2025 · Duloxetine
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above safety assessment limit
Duloxetine Delayed-Release Capsules, USP, 60mg, 1,000-count bottles, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Distributed by: Breckenridge Pharmaceuticals, Inc., Berkeley Height
-
June 30, 2025 · Class II · Ongoing · D-0511-2025 · Duloxetine
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Duloxetine Delayed-Release Capsules, USP, 40mg, 30-count bottles, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 079
-
April 14, 2025 · Class II · Ongoing · D-0388-2025 · Duloxetine
CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.
Duloxetine Delayed-Release Capsules USP, 30 mg, a.) 90-count bottles (NDC# 51991-747-90), b.) 1000-count bottles (NDC 51991-747-10), Rx Only, Manufactured by Towa Pharmaceutical Europe, S.L. Distributed by Breckenridge P
-
April 14, 2025 · Class II · Ongoing · D-0387-2025 · Duloxetine
CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.
Duloxetine Delayed-Release Capsules USP, 60 mg, 1000-count bottles, Rx Only, Manufactured by Towa Pharmaceutical Europe, S.L., Distributed by Breckenridge Pharmaceutical, Inc. Berkeley Heights, NJ 07922, NDC# 51991-748-1
-
March 26, 2025 · Class II · Ongoing · D-0308-2025 · Duloxetine
CGMP Deviations: presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the recommended interim limit.
Duloxetine Delayed-Release Capsules, USP, 30 mg, Rx Only, 1,000 Capsules per bottle, Manufactured by: Towa Pharmaceutical Europe, S.L., Martorelles, (Barcelona), Spain, Distributed by: Breckenridge Pharmaceutical, Inc.,
Show the 11 older recalls
2025
-
February 28, 2025 · Class II · Ongoing · D-0271-2025 · Duloxetine
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
Duloxetine Delayed-Release Capsules, USP, 20mg, Rx Only, 500-count bottles, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07
-
February 28, 2025 · Class II · Ongoing · D-0269-2025 · Duloxetine
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
Duloxetine Delayed-Release Capsules, USP, 60mg, Rx Only, 1000-count bottles, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 0
-
February 28, 2025 · Class II · Ongoing · D-0270-2025 · Duloxetine
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
Duloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, 1000-count bottles, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 0
2024
-
December 6, 2024 · Class II · Ongoing · D-0162-2025 · Duloxetine
CGMP Deviations: presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
Duloxetine Delayed-Release Capsules, USP, 60 mg, Rx Only, 90-count bottles (NDC 51991-748-90) Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berke
-
December 6, 2024 · Class II · Ongoing · D-0161-2025 · Duloxetine
CGMP Deviations: presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
Duloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, 90-count bottles (NDC 51991-747-90) Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkel
-
October 10, 2024 · Class II · Completed · D-0009-2025 · Duloxetine
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Duloxetine Delayed-Release Capsules, USP, 20mg, Rx Only, 500-count bottles, Mfr. by: Towa Pharmaceutical Europe, S.L. Distributed by: BPI, NDC 51991-746-05.
-
May 17, 2024 · Class II · Terminated · D-0562-2024 · Duloxetine
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Duloxetine Delayed-Release Capsules, USP, 60mg, 90-count bottle, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 0792
-
April 29, 2024 · Class II · Ongoing · D-0484-2024 · Duloxetine
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Duloxetine Delayed-Release Capsules, USP, 60 mg, 90-count bottles, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07
-
April 29, 2024 · Class II · Ongoing · D-0482-2024 · Duloxetine
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Duloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, (a) 90-count bottles (NDC 51991-747-90), (b) 1000-count bottles (NDC 51991-747-10), Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist
-
April 29, 2024 · Class II · Ongoing · D-0483-2024 · Duloxetine
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Duloxetine Delayed-Release Capsules, USP, 20 mg, , 500-count bottles, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ
2015
-
October 21, 2015 · Class III · Terminated · D-0181-2016 · Duloxetine
Presence of Foreign Tablets/Capsules: one foreign capsule identified as omeprazole 10 mg was found in the bottle
Duloxetine Delayed-release Capsules, USP, 60 mg, Rx Only, 1000 count bottle, Manufactured by: Laboratorios Dr. Esteve, S.A., Barcelona, Spain, Distributed by: Breckenridge Pharmaceutical, Inc., Boca Raton, FL 33487, NDC:
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Next steps
- Find a pharmacy near youAsk which company made your medicine and whether it is recalled
- Latest FDA drug recallsAll companies, newest first
- All drug companiesA to Z
- All prescription drugs A to ZSearch by generic, brand or Spanish name
Sources
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026